Checkpoint inhibition: protecting against or predisposing for second primary tumors?
- PMID: 33794292
- DOI: 10.1016/j.annonc.2021.03.202
Checkpoint inhibition: protecting against or predisposing for second primary tumors?
Conflict of interest statement
Disclosure KPMS has advisory relationships with Bristol-Myers Squibb, Novartis, MSD, Pierre Fabre, and AbbVie and received honoraria from Novartis and Roche, all outside the submitted work and paid to institution. All other authors have declared no conflicts of interest.
Comment in
-
Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs.Ann Oncol. 2021 Aug;32(8):1055-1057. doi: 10.1016/j.annonc.2021.04.017. Epub 2021 Apr 28. Ann Oncol. 2021. PMID: 33932506 No abstract available.
Comment on
-
Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer.Ann Oncol. 2020 Dec;31(12):1773-1775. doi: 10.1016/j.annonc.2020.09.001. Epub 2020 Sep 9. Ann Oncol. 2020. PMID: 32916266 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical